Nucleic acids for apoptosis of cancer cells

• US 20060183893A1
• Filed: 12/19/2005
• Published: 08/17/2006
• Est. Priority Date: 01/25/2005
• Status: Abandoned Application

• Current Assignee: Sky Genetics, Inc.
• Original Assignee: Sky Genetics, Inc.
• Inventors: North, Don Adams
• Application Number:
  US11/311,594
• Publication Number:
  US 20060183893A1
• Time in Patent Office: Days
• US Class Current: 536/23.500
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The disclosure relates to a nucleic acid having an Apoptotic Sequence of: Seq. ID. No:1, Seq. ID. No:2, Seq. ID. No:3, Seq. ID. No:4, Seq. ID. No: 5, Seq. ID. No:6, and Seq. ID. No:7. It also relates to a compsoition including a nucleic acid having an Apoptotic Sequence of Seq. ID. No:1, Seq. ID. No:2, Seq. ID. No:3, Seq. ID. No:4, Seq. ID. No: 5, Seq. ID. No:6, and Seq. ID. No:7. The composition may also include a pharmaceutically acceptable carrier. The disclosure also includes a method of killing a cancer cell by administering to a cancer cell a serum including a nucleic acid having an Apoptotic Sequence of: Seq. ID. No:1, Seq. ID. No:2, Seq. ID. No:3, Seq. ID. No:4, Seq. ID. No: 5, Seq. ID. No:6, and Seq. ID. No:7 and a pharmaceutically acceptable carrier. The cancer cell may be located in a subject with cancer.

Claims

1. A nucleic acid having a sequence selected from the group consisting of:

Seq. ID. No;

1, Seq. ID. No;

2, Seq. ID. No;

3, Seq. ID. No;

4, Seq. ID. No;

5, Seq. ID. No;

6, and Seq. ID. No;

7.

2. A nucleic acid according to claim 1, wherein the nucleic acid comprises DNA.

3. A nucleic acid according to claim 2, wherein the nucleic acid comprises single stranded DNA.

6. A composition according to claim 3, wherein the nucleic acid comprises single stranded DNA.

4. A composition comprising:

a nucleic acid having a sequence selected from the group consisting of;

Seq. ID. No;

1, Seq. ID. No;

2, Seq. ID. No;

3, Seq. ID. No;

4, Seq. ID. No;

5, Seq. ID. No;

6, and Seq. ID. No;

7; and

a pharmaceutically acceptable carrier.

5. A composition according to claim 4, wherein the nucleic acid comprises DNA.

7. A composition according to claim 4, comprising at least one additional nucleic acid having a sequence selected from the group consisting of:

Seq. ID. No;

1, Seq. ID. No;

2, Seq. ID. No;

3, Seq. ID. No;

4, Seq. ID. No;

5, Seq. ID. No;

6, and Seq. ID. No;

7.

8. A composition according to claim 4, further comprising a chemotherapeutic or radiotherapeutic.

9. A composition according to claim 4, comprising a liquid carrier and the nucleic acid in a concentration of between about 0.17 mg/ml and 1.7 mg/ml.

10. A composition according to claim 4, comprising the nucleic acid in a concentration of about 10 mg/ml.

11. A composition according to claim 4, wherein the pharmaceutically acceptable carrier comprises phosphate buffered saline (PBS) or artificial cerebrospinal fluid (CSF).

12. A method of killing a cancer cell comprising administering to a cancer cell a serum including a nucleic acid having a sequence selected from the group consisting of:

Seq. ID. No;

1, Seq. ID. No;

2, Seq. ID. No;

3, Seq. ID. No;

4, Seq. ID. No;

5, Seq. ID. No;

6, and Seq. ID. No;

7; and

a pharmaceutically acceptable carrier.

13. A method according to claim 12, wherein the cancer cell is located in a subject with cancer.

14. A method according to claim 12, comprising administering a serum also including a second nucleic acid having a sequence selected from the group consisting of:

Seq. ID. No;

2, Seq. ID. No;

3, Seq. ID. No;

4, and Seq. ID. No;

5.

15. A method according to claim 12, comprising administering to a cancer cell a second serum having a second sequence selected from the group consisting of:

Seq. ID. No;

1, Seq. ID. No;

2, Seq. ID. No;

3, Seq. ID. No;

4, Seq. ID. No;

5, Seq. ID. No;

6, and Seq. ID. No;

7.

16. A method according to claim 13, further comprising administering the nucleic acid in a dose of between about 5 mg and 50 mg of nucleic acid per kg of subject.

17. A method according to claim 13, further comprising administering the nucleic acid in an amount effective to kill a cancer cell, but at at dose less than about 25 mg of nucleic acid per kg of subject.

18. A method according to claim 12, further comprising administering the serum weekly.

19. A method according to claim 13, further comprising testing the subject for cancer cells including a nucleic acid having the sequence of the nucleic acid of the serum and administering the serum if the sequence is present.

20. A method according to claim 12, wherein administering comprises administering by intravenous drip.